Cargando…
An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance
BACKGROUND: Schizophrenia remains a priority condition in mental health policy and service development because of its early onset, severity and consequences for affected individuals and households. AIMS AND METHODS: This paper reports on an ‘extended’ cost-effectiveness analysis (ECEA) for schizophr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938947/ https://www.ncbi.nlm.nih.gov/pubmed/27398070 http://dx.doi.org/10.1186/s12962-016-0058-z |
_version_ | 1782441931381407744 |
---|---|
author | Raykar, Neha Nigam, Aditi Chisholm, Dan |
author_facet | Raykar, Neha Nigam, Aditi Chisholm, Dan |
author_sort | Raykar, Neha |
collection | PubMed |
description | BACKGROUND: Schizophrenia remains a priority condition in mental health policy and service development because of its early onset, severity and consequences for affected individuals and households. AIMS AND METHODS: This paper reports on an ‘extended’ cost-effectiveness analysis (ECEA) for schizophrenia treatment in India, which seeks to evaluate through a modeling approach not only the costs and health effects of intervention but also the consequences of a policy of universal public finance (UPF) on health and financial outcomes across income quintiles. RESULTS: Using plausible values for input parameters, we conclude that health gains from UPF are concentrated among the poorest, whereas the non-health gains in the form of out-of-pocket private expenditures averted due to UPF are concentrated among the richest income quintiles. Value of insurance is the highest for the poorest quintile and declines with income. CONCLUSIONS: Universal public finance can play a crucial role in ameliorating the adverse economic and social consequences of schizophrenia and its treatment in resource-constrained settings where health insurance coverage is generally poor. This paper shows the potential distributional and financial risk protection effects of treating schizophrenia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12962-016-0058-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4938947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49389472016-07-10 An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance Raykar, Neha Nigam, Aditi Chisholm, Dan Cost Eff Resour Alloc Research BACKGROUND: Schizophrenia remains a priority condition in mental health policy and service development because of its early onset, severity and consequences for affected individuals and households. AIMS AND METHODS: This paper reports on an ‘extended’ cost-effectiveness analysis (ECEA) for schizophrenia treatment in India, which seeks to evaluate through a modeling approach not only the costs and health effects of intervention but also the consequences of a policy of universal public finance (UPF) on health and financial outcomes across income quintiles. RESULTS: Using plausible values for input parameters, we conclude that health gains from UPF are concentrated among the poorest, whereas the non-health gains in the form of out-of-pocket private expenditures averted due to UPF are concentrated among the richest income quintiles. Value of insurance is the highest for the poorest quintile and declines with income. CONCLUSIONS: Universal public finance can play a crucial role in ameliorating the adverse economic and social consequences of schizophrenia and its treatment in resource-constrained settings where health insurance coverage is generally poor. This paper shows the potential distributional and financial risk protection effects of treating schizophrenia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12962-016-0058-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-08 /pmc/articles/PMC4938947/ /pubmed/27398070 http://dx.doi.org/10.1186/s12962-016-0058-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Raykar, Neha Nigam, Aditi Chisholm, Dan An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance |
title | An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance |
title_full | An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance |
title_fullStr | An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance |
title_full_unstemmed | An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance |
title_short | An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance |
title_sort | extended cost-effectiveness analysis of schizophrenia treatment in india under universal public finance |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938947/ https://www.ncbi.nlm.nih.gov/pubmed/27398070 http://dx.doi.org/10.1186/s12962-016-0058-z |
work_keys_str_mv | AT raykarneha anextendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance AT nigamaditi anextendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance AT chisholmdan anextendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance AT raykarneha extendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance AT nigamaditi extendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance AT chisholmdan extendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance |